(Q60302456)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

8 February 2021

Immune checkpoint inhibitors: recent progress and potential biomarkers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

0 references

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Eyad Elkord

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

author name string

Salman M Toor

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Varun Sasidharan Nair

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

language of work or name

English

0 references

publication date

13 December 2018

6 references

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

9 September 2020

8 February 2021

Experimental and Molecular Medicine

6 references

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

9 September 2020

8 February 2021

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

14 April 2020

copyright license

4 references

27 September 2019

27 November 2019

13 December 2019

8 February 2021

0 references

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Checkpoint inhibitors in breast cancer - Current status

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Elements of cancer immunity and the cancer-immune set point

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Hallmarks of response to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Effector memory T cells, early metastasis, and survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Classifying Cancers Based on T-cell Infiltration and PD-L1.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Biomarkers of response to PD-1/PD-L1 inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Mechanisms of resistance to immune checkpoint inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Epigenetics: reversible tags.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Causes and consequences of microRNA dysregulation in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

The role of the miR-200 family in epithelial-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS12276-018-0191-1

7 January 2021

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30546008

12 December 2020

inferred from PubMed ID database lookup

PDL1 Regulation by p53 via miR-34

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30546008

12 December 2020

inferred from PubMed ID database lookup

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30546008

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/S12276-018-0191-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

14 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30546008%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

30546008

1 reference